Skip to main content
. 2020 Sep 11;11(11):2146–2150. doi: 10.1021/acsmedchemlett.0c00220

Table 2. IC50 Values of the Tested Compounds against Noncancerous HEK293 and Hep G2 Liver Carcinoma Cells.

  IC50, μM
  
Compound Hep G2 HEK293 Selectivity HEK293/Hep G2
(+)-JV-976 11.7 ± 3.2 >100 >10
(−)-JV-976 17.4 ± 8.4 53.3 ± 24 3.1
JV-982 9.4 ± 2.0 25.6 ± 3.1 2.7
Cabozantinib 8.3 ± 2.7 25.8 ± 13.3 3.1